Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase III ASCEMBL Study

被引：0

作者：

Mauro, Michael ^{[1
]}

Hochhaus, Andreas ^{[2
]}

Hughes, Timothy ^{[3
,4
]}

Rea, Delphine ^{[5
]}

Boquimpani, Carla ^{[6
]}

Minami, Yosuke ^{[7
]}

Apperley, Jane ^{[8
]}

Garcia-Gutierrez, Valentin ^{[9
]}

Kapoor, Shruti ^{[10
]}

Espurz, Noemi ^{[11
]}

Dhamal, Vishal ^{[12
]}

Cortes, Jorge ^{[13
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Univ Klinikum Jena, Jena, Germany

[3] South Australian Hlth & Med Res Inst, Adelaide, SA, Australia

[4] Univ Adelaide, Adelaide, SA, Australia

[5] Hop St Louis, Paris, France

[6] State Inst Hematol Arthur Siquiera Cavalcanti, HEMORIO, Rio De Janeiro, Brazil

[7] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[8] Ctr Haematol Imperial Coll London, London, England

[9] Hosp Univ Ramon & Cajal IRYCIS, Serv Hematol, Madrid, Spain

[10] Novartis Pharmaceut, E Hanover, NJ USA

[11] Novartis Pharma AG, Basel, Switzerland

[12] Novartis Healthcare Private Ltd, Hyderabad, India

[13] Georgia Canc Ctr, Augusta, GA USA

来源：

关键词：

CML; asciminib; TKI; ASCEMBL; phase III;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CML-398

引用

页码：S340 / S340

页数：1